DENTSPLY SIRONA earnings release, August 7, 2026

DENTSPLY SIRONA Inc. (XRAY) · Form 8-K/A, Item 2.02 · Filed · SEC filing

Dentsply Sirona Reports Second Quarter 2026

Results

News Summary

• Reported net sales of $898 million

• Delivered GAAP gross margin of 54.9%, GAAP diluted earnings per share of $0.18

• Achieved adjusted gross margin of 56.4%, adjusted EBITDA margin of 21.3%, adjusted EPS of $0.52

• Announced expanded partnership with Medline Sinclair, broadening access to Connected Technology Solutions portfolio across Canada

• Repurchased 1.3 million shares of common stock during the quarter

• Reiterates 2026 outlook for net sales and adjusted EPS

Charlotte, N.C., August 6, 2026 -

DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced its financial results for the second quarter of 2026.

"2026 continues to be a year of decisive action as we execute our Return-to-Growth Action Plan," said Dan Scavilla, President and Chief Executive Officer of Dentsply Sirona. "We are making meaningful progress in our highest priority areas, including strengthening and expanding our distributor relationships, realigning our sales teams, and reinvesting in the business. Our second quarter results were in line with expectations and we continue to strengthen the financial foundation of the company. As our work gains traction, we remain focused on executing our strategy with discipline to drive sustained, profitable growth."

Q2 2026 Summary Results (Reported)

Q2 2026 Summary Results (Non-GAAP)

NM - not meaningful

Percentages are based on actual values and may not reconcile due to rounding.

[1]

Weighted-average shares outstanding used to calculate diluted loss per share for the second quarter of 2025 excludes potential dilutive common shares.

Q2 2026 Results by Region and Segment (Reported and Non-GAAP)

(in millions, except percentages)

Cash Flow and Liquidity

Operating cash flow in the second quarter of 2026 was $99 million, compared to $48 million in the second quarter of 2025, primarily due to the receipt of approximately $44 million in tariff refunds and improved management of inventory and accounts payable. Free cash flow, a Non-GAAP measure, in the second quarter of 2026 was $55 million compared to $16 million in the second quarter of 2025. The Company repurchased 1.3 million shares of its common stock for a total of approximately $12 million in the second quarter of 2026. The Company had $239 million of cash and cash equivalents as of June 30, 2026.

2026 Outlook

The Company is maintaining its 2026 outlook for net sales in the range of $3.5 billion to $3.6 billion and adjusted EPS in the range of $1.40 to $1.50. The benefits of refunds for tariffs are not included in the outlook for 2026 adjusted EPS.

We are unable to present a quantitative reconciliation of our expected earnings per diluted share to expected adjusted earnings per diluted share as we are unable to predict with reasonable certainty and without unreasonable effort, items which may include, but are not limited to, restructuring charges, transformation-related costs, impairment charges, certain tax adjustments, and other significant items. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our Consolidated Statements of Operations.

Conference Call/Webcast Information

Dentsply Sirona's management team will host an investor conference call and live webcast on August 6, 2026, at 4:30 p.m. ET. The live webcast and a presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com.

For those planning to participate on the call, please register at https://register-conf.media-server.com/register/BIa20adbc738174810a6f4b3ce44466cfa. A webcast replay of the conference call will be available on the Investors section of the Company's website following the call.

About Dentsply Sirona

Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering, including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona's innovative products provide high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona is headquartered in Charlotte, North Carolina. The Company's shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.

Contact Information:

Investors:

Wade Moody

Senior Manager, Investor Relations

Investorrelations@dentsplysirona.com

Press:

Marion Par-Weixlberger

Vice President, Public Relations, Corporate Communications & Brand

Publicrelations@dentsplysirona.com

Financial statements

Income Statement

Q2 2026 Summary Results (Reported) (in millions, except per share amount and percentages)

Q2 26Q2 25YoY
Net Sales898936-4.1%
Gross Profit4934900.6%
Gross Margin54.9%52.4%
Net Income (Loss) Attributable to Dentsply Sirona37-45NM
Diluted Earnings (Loss) Per Share10.18-0.22NM

Income Statement

Three Months Ended June 30, — (unaudited)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net sales8989361,7781,815
Cost of products sold405446858859
Gross profit493490920956
Selling, general, and administrative expenses364342715700
Research and development expenses45378973
Goodwill and intangible asset impairments235235
Restructuring and other costs246913
Operating income (loss)82-12847-65
Other income and expenses:Interest expense, net22244643
Other income and expenses:Other (income) expense, net-121-291
Other income and expenses:Income (loss) before income taxes72-15330-109
Other income and expenses:Provision (benefit) for income taxes36-1094-84
Other income and expenses:Net income (loss)36-4426-25
Other income and expenses:Less: Net (loss) income attributable to noncontrolling interest-11-1
Other income and expenses:Net income (loss) attributable to Dentsply Sirona37-4527-25
Earnings (loss) per common share attributable to Dentsply Sirona:Basic0.18-0.220.14-0.13
Earnings (loss) per common share attributable to Dentsply Sirona:Diluted0.18-0.220.14-0.13
Weighted average common shares outstanding:Basic199.7199.3199.8199.2
Weighted average common shares outstanding:Diluted200.5199.3200.8199.2

Income Statement

Three Months Ended June 30, 2026

Three Months Ended June 30, 2026 – Gross ProfitThree Months Ended June 30, 2026 – Operating IncomeThree Months Ended June 30, 2026 – Provision for Income TaxesThree Months Ended June 30, 2026 – Net Income Attributable to Dentsply SironaThree Months Ended June 30, 2026 – Diluted Earnings per Share
Reported4938236370.18
Reported percent net sales54.99.1
Non-GAAP Adjustments:Amortization of Purchased Intangible Assets124912370.18
Non-GAAP Adjustments:Restructuring-Related Charges and Other Costs (a)10370.05
Non-GAAP Adjustments:Business Combination-Related Costs111
Non-GAAP Adjustments:Income Tax-Related Adjustments (b)-21210.11
Non-GAAP Adjustments:Adjusted506142301030.52
Non-GAAP Adjustments:Adjusted percent net sales56.415.8

Income Statement

Three Months Ended June 30, 2025 — Percentages are based on actual values and may not reconcile due to rounding.

Three Months Ended June 30, 2025 – Gross ProfitThree Months Ended June 30, 2025 – Operating (Loss) IncomeThree Months Ended June 30, 2025 – (Benefit) Provision for Income TaxesThree Months Ended June 30, 2025 – Net (Loss) Income Attributable to Dentsply SironaThree Months Ended June 30, 2025 – Diluted (Loss) Earnings per Share
Reported490-128-109-45-0.22
Reported percent net sales52.4-13.7
Non-GAAP Adjustments:Amortization of Purchased Intangible Assets325414400.2
Non-GAAP Adjustments:Restructuring-Related Charges and Other Costs (a)514
Non-GAAP Adjustments:Goodwill and Intangible Asset Impairments235212141.07
Non-GAAP Adjustments:Business Combination-Related Costs14130.01
Non-GAAP Adjustments:Fair Value and Credit Risk Adjustments-4
Non-GAAP Adjustments:Income Tax-Related Adjustments (b)107-107-0.54
Non-GAAP Adjustments:Adjusted523170351050.52
Non-GAAP Adjustments:Adjusted percent net sales55.918.2

Income Statement

Three Months Ended June 30, — Reconciliations of reported net income (loss) attributable to Dentsply Sirona to adjusted EBITDA and margin are as follows:

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025
Net income (loss) attributable to Dentsply Sirona37-45
Interest expense, net2224
(Benefit) provision for income taxes36-109
Depreciation(1)3533
Amortization of intangible assets4954
Restructuring-related charges and other costs105
Goodwill and intangible asset impairments235
Business combination-related costs and fair value adjustments14
Fair value and credit risk adjustments-4
Adjusted EBITDA190197
Net sales898936
Adjusted EBITDA margin21.321.1

Balance Sheet

June 30, 2026 — (unaudited)

June 30, 2026December 31, 2025
Current Assets:Cash and cash equivalents239326
Current Assets:Accounts and notes receivable-trade, net620688
Current Assets:Inventories, net665642
Current Assets:Prepaid expenses and other current assets404367
Current Assets:Total Current Assets1,9282,023
Current Assets:Property, plant, and equipment, net845861
Current Assets:Operating lease right-of-use assets, net129139
Current Assets:Identifiable intangible assets, net870974
Current Assets:Goodwill1,1381,148
Current Assets:Other noncurrent assets294284
Current Assets:Total Assets5,2045,429
Current Liabilities:Accounts payable260300
Current Liabilities:Accrued liabilities664700
Current Liabilities:Income taxes payable3330
Current Liabilities:Notes payable and current portion of long-term debt228313
Current Liabilities:Total Current Liabilities1,1851,343

Cash Flow

Six Months Ended June 30, — (unaudited)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Cash flows from operating activities:Net income (loss)26-25
Adjustments to reconcile net loss to net cash provided by operating activities:Depreciation7468
Adjustments to reconcile net loss to net cash provided by operating activities:Amortization of intangible assets9099
Adjustments to reconcile net loss to net cash provided by operating activities:Goodwill asset impairment156
Adjustments to reconcile net loss to net cash provided by operating activities:Indefinite-lived intangible asset impairment79
Adjustments to reconcile net loss to net cash provided by operating activities:Deferred income taxes-42-136
Adjustments to reconcile net loss to net cash provided by operating activities:Stock-based compensation expense1719
Adjustments to reconcile net loss to net cash provided by operating activities:Other non-cash (income) expense-1319
Adjustments to reconcile net loss to net cash provided by operating activities:Gain on disposal of assets-6
Changes in operating assets and liabilities:Accounts and notes receivable-trade, net56-31
Changes in operating assets and liabilities:Inventories, net-32-47
Changes in operating assets and liabilities:Prepaid expenses and other current assets-1126
Changes in operating assets and liabilities:Other noncurrent assets-21
Changes in operating assets and liabilities:Accounts payable16-10
Changes in operating assets and liabilities:Accrued liabilities-38-35
Changes in operating assets and liabilities:Income taxes4-55
Changes in operating assets and liabilities:Other noncurrent liabilities-73
Changes in operating assets and liabilities:Net cash provided by operating activities13955
Cash flows from investing activities:Capital expenditures-96-51
Cash flows from investing activities:Cash received on derivative contracts1
Cash flows from investing activities:Cash paid on derivative contracts-2
Cash flows from investing activities:Net investment hedge settlements-8
Cash flows from investing activities:Proceeds from sale of property, plant, and equipment51
Cash flows from investing activities:Other investing activities7
Cash flows from investing activities:Net cash used in investing activities-92-51
Cash flows from financing activities:Cash paid for treasury stock-12
Cash flows from financing activities:Proceeds from 364-day bridge loan435
Cash flows from financing activities:Repayment of 364-day bridge loan-435
Cash flows from financing activities:Repayments on short-term borrowings-50-413
Cash flows from financing activities:Cash dividends paid-32-64
Cash flows from financing activities:Proceeds from long-term borrowings550
Cash flows from financing activities:Repayments on long-term borrowings-31-2
Cash flows from financing activities:Cash paid for deferred financing costs-13
Cash flows from financing activities:Other financing activities, net-5-3
Cash flows from financing activities:Net cash (used in) provided by financing activities-13055
Cash flows from financing activities:Effect of exchange rate changes on cash and cash equivalents-428
Cash flows from financing activities:Net (decrease) increase in cash and cash equivalents-8787
Cash flows from financing activities:Cash and cash equivalents at beginning of period326272
Cash flows from financing activities:Cash and cash equivalents at end of period239359
Supplemental disclosures of cash flow information:Interest paid, net of amounts capitalized4343
Non-cash investing activities:Property, plant and equipment in accounts payable at end of period1925
Non-cash investing activities:Exchange of inventory for naming and other rights14

Cash Flow

Three Months Ended June 30, — A reconciliation of free cash flow for the three months ended June 30, 2026 and 2025 is as follows:

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025
Net cash provided by operating activities9948
Capital expenditures-44-32
Free cash flow5516
Full release

Forward-Looking Statements and Associated Risks... (truncated)re made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this Press Release or to reflect the occurrence of unanticipated events. Investors should understand it is not possible to predict or identify all such factors or risks. As such, you should not consider the risks identified in the Company's SEC filings to be a complete discussion of all potential risks or uncertainties associated with an investment in the Company.

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.